Back
Cançado GGL, et al. 2025. High biochemical remission rates in patients with primary biliary cholangitis treated with "triple" anticholestatic therapy. Hepatol Commun (Oct 2025)
Zhang Z, Yang Z. 2025. Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others? Hepatol Res (Sep 2025)
Abbas N, et al. 2025. Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Sep 2025)
Sirohi N, et al. 2025. Dismal Prognosis of Primary Biliary Cholangitis and Its Overlap with Autoimmune Hepatitis. J Clin Exp Hepatol (2025)
Nie Y, et al. 2025. Gut Microbiota: Implications in Pathogenesis and Potential Therapeutic Target in Primary Biliary Cholangitis. J Clin Transl Hepatol (Sep 2025)
Zhang W, et al. 2025. A Bibliometric Analysis of Immunological Research in Primary Biliary Cholangitis: Global Patterns and Emerging Directions. Cureus (Aug 2025)
Zhang M, et al. 2025. Genetic architecture of primary biliary cholangitis: strong evidence for HLA and non-HLA risk loci. Front Immunol (2025)
Kugiyama Y, et al. 2025. Clinical Characteristics and Long-Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd-Generation Nationwide Survey. Hepatol Res (Sep 2025)
Brice C, Louvet A. 2025. [New therapeutic approaches for the treatment of primary biliary cholangitis]. Med Sci (Paris) (2025)
Liao W, et al. 2025. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis. Therap Adv Gastroenterol (2025)
Memon A, et al. 2025. A comprehensive review of systemic sclerosis-primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype. Curr Opin Rheumatol (Sep 2025)
Wang X, et al. 2025. Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China. Clin Rheumatol (Sep 2025)
Herta T, Berg T. 2025. [Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options]. Inn Med (Heidelb) (Sep 2025)
Pan SD, et al. 2025. MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid. World J Gastroenterol (Aug 2025)
Han HQ, et al. 2025. Peripheral basophil activation: A hidden player in the immunopathogenesis of primary biliary cholangitis. World J Hepatol (Aug 2025)
Abuelazm M, et al. 2025. The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. JGH Open (Sep 2025)
Del Barrio M, et al. 2025. Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression. Int J Mol Sci (Aug 2025)
Buck L, et al. 2025. An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis. Sci Rep (Aug 2025)
Ding D, et al. 2025. Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria. J Transl Int Med (Aug 2025)
Lu W, et al. 2026. Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis. Clin Chim Acta (Jan 2026)
Abid S, et al. 2025. Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape. Ann Med Surg (Lond) (Jul 2025)
Chen PT, Chen HW. 2025. Reply to "Comment on risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Aug 2025)
Zeng Z, et al. 2025. Integrating Machine Learning and Multi-Omics Analyses to Identify Immune-Related Biomarkers and Mechanisms in Primary Biliary Cholangitis. Clin Transl Gastroenterol (Aug 2025)
Chen W, et al. 2025. Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics. Front Med (Lausanne) (2025)
Okumura T, et al. 2025. Prognostic Significance of Bile Duct Loss in Early-Stage Primary Biliary Cholangitis: A Long-Term Observational Study. Hepatol Res (Aug 2025)
Ashraf T, et al. 2025. Correction: The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis. BMC Gastroenterol (Aug 2025)
Zou M, et al. 2025. Insights into the association between primary biliary cholangitis and colorectal neoplasia: More details, more significance. J Formos Med Assoc (Aug 2025)
Li S, et al. 2025. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels. Clin Chem Lab Med (Aug 2025)
Zingone F, et al. 2025. Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Liver Int (Sep 2025)
Sierra L, et al. 2025. Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: A United States cohort. Ann Hepatol (Aug 2025)
Rogalska M, et al. 2025. Elevated Plasma BDNF in Early Primary Biliary Cholangitis: Associations with Liver Fibrosis, IL-6, IL-18, Fatigue, and Cognitive Impairment. Int J Mol Sci (Jul 2025)
Miglianti M, et al. 2025. The role of HLA-G in primary biliary cholangitis and response to therapy. Front Immunol (2025)
Said E, et al. 2025. Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation. Cureus (Jul 2025)
Zhu HL, et al. 2025. [Predictive value of neutrophil/lymphocyte ratio in the prognosis of primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Ran Y, et al. 2025. [Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Ma L, et al. 2025. [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Koky T, et al. 2025. Early assessment of treatment response in primary biliary cholangitis: key to timely management. BMC Gastroenterol (Aug 2025)
Shukla AK, Misra S. 2025. Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. J Basic Clin Physiol Pharmacol (Aug 2025)
Zhang J, et al. 2025. Dendritic Cell-Depleted Mice Develop the Autoimmune Biliary Disease That Serologically and Pathogenically Models Human Primary Biliary Cholangitis. Hepatol Res (Aug 2025)
Ando Y, et al. 2025. Anti-centromere antibody positivity with coexisting idiopathic portal hypertension and primary biliary cholangitis progressing to limited cutaneous systemic sclerosis: a case report. J Med Case Rep (Aug 2025)
Kobayashi Y, et al. 2025. Acute-on-chronic liver failure in primary biliary cholangitis by exacerbation of autoimmune hepatitis features. Clin J Gastroenterol (Oct 2025)
Lei X, et al. 2025. A case of membranous nephropathy complicated by autoimmune hepatitis and primary biliary cholangitis. Medicine (Baltimore) (Aug 2025)
Haddadin R, et al. 2025. Diagnostic Challenges in Concurrent Primary Biliary Cholangitis and Secondary Syphilis: A Case Report. J Community Hosp Intern Med Perspect (2025)
Li SX, et al. 2025. GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate. J Dig Dis (May 2025)
Zang B, et al. 2025. Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis. World J Hepatol (Jul 2025)
Mitchell NE, et al. 2025. Evolving therapeutic landscape of primary biliary cholangitis: A review. World J Hepatol (Jul 2025)
Gelhorn H, et al. 2025. Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis. Orphanet J Rare Dis (Jul 2025)
Ren W, et al. 2025. Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis. BMC Gastroenterol (Jul 2025)
Floreani A, et al. 2025. Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis. Expert Rev Gastroenterol Hepatol (Aug 2025)
Cho EJ. 2025. Emerging Therapeutics for Primary Biliary Cholangitis. Korean J Gastroenterol (Jul 2025)
Rogalska M, et al. 2025. Clinical characteristics of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Pol Arch Intern Med (Sep 2025)
Pu X, et al. 2025. B cells drive CCR5CD4 tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis. J Hepatol (Jul 2025)
Abulitifu Y, et al. 2025. The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial. BMC Gastroenterol (Jul 2025)
Wei Y, et al. 2025. Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience. Clin Rheumatol (Sep 2025)
Rigopoulou EI, et al. 2025. IgG Baseline Serum Levels and Prognosis of Primary Biliary Cholangitis. Liver Int (Aug 2025)
Khadijat-Ul-Kurba H, et al. 2025. Atorvastatin unveiling primary biliary cholangitis and autoimmune hepatitis overlap syndrome in an older adult: A case report. Malays Fam Physician (2025)
Feng J, et al. 2025. [Research progress on the diagnostic performance and predictive accuracy of different prognostic scores as non-invasive liver fibrosis models for primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jun 2025)
Untas A, et al. 2025. PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue. Am J Gastroenterol (Jul 2025)
Men X, et al. 2025. The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine. Clin Rev Allergy Immunol (Jul 2025)
Liu W, et al. 2025. Causal relationship between primary biliary cholangitis on osteoporosis: A two-sample Mendelian randomization study. Medicine (Baltimore) (Jul 2025)
Elbasheer A, Ahmed SMM. 2025. Hepatic Encephalopathy Induced by Small Bowel Obstruction in a Patient With Primary Biliary Cholangitis. Cureus (Jul 2025)
Da TT, et al. 2025. A novel subset of inflammation-related liver NK cells modulates immune responses in a murine model of primary biliary cholangitis. J Autoimmun (Jul 2025)
Yuan S, et al. 2025. Letter to the editor: the causal effects of primary biliary cholangitis on irritable bowel syndrome a mendelian randomization study. Int J Surg (Jul 2025)
Yang YS, et al. 2025. Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis. World J Hepatol (Jun 2025)
Li Z, et al. 2025. Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Assessing Liver Function in Primary Biliary Cholangitis. Curr Med Imaging (Jun 2025)
Huang LX, et al. 2025. Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis. Sci Rep (Jul 2025)
Qin X, Jin Z. 2025. Progress and Perspectives in Overlapping Primary Biliary Cholangitis and Autoimmune Hepatitis: A Comprehensive Review. J Gastrointestin Liver Dis (Jun 2025)
Zhao P, et al. 2025. Comments to the Editor: opinions on "Causal effects of primary biliary cholangitis on irritable bowel syndrome: a Mendelian randomization study". Int J Surg (Sep 2025)
Reshetnyak VI, et al. 2025. Primary biliary cholangitis: A historical perspective from xanthomatous lesions to modern molecular biology. World J Gastrointest Pathophysiol (Jun 2025)
Mazhuvanchery C, et al. 2025. Triple Threat: The Importance of Diagnosing "Triple-Negative" Primary Biliary Cholangitis. Dig Dis Sci (Jun 2025)
Levy C, et al. 2025. Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Am J Gastroenterol (Jun 2025)
Deng Z, et al. 2025. Primary Biliary Cholangitis and Seropositive Rheumatoid Arthritis: A Two-Sample Mendelian Randomization Study. Clin Exp Gastroenterol (2025)
Caines A, et al. 2025. Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. J Gastroenterol Hepatol (Sep 2025)
Zhang C, et al. 2025. Commentary on "The causal effects of primary biliary cholangitis on irritable bowel syndrome: a Mendelian randomization study". Int J Surg (Jun 2025)
Nakajima T, et al. 2025. Eradication Therapy-Associated Drug-Induced Liver Injury in a Patient With Primary Biliary Cholangitis. Gastro Hep Adv (2025)
Lin H, et al. 2025. Lymphocyte-to-Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis. Aliment Pharmacol Ther (Sep 2025)
Russo MW. 2025. Second-Line but Not Second Rate: Fibrates for the Treatment of Patients with Primary Biliary Cholangitis. Dig Dis Sci (Jun 2025)
Zeng X, et al. 2025. Letter to the Editor: A commentary on "The causal effects of primary biliary cholangitis on irritable bowel syndrome a Mendelian randomization study". Int J Surg (Sep 2025)
Chaudhuri U, et al. 2025. Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine. Cureus (May 2025)
Cançado GGL, et al. 2025. Primary biliary cholangitis and the narrowing gap towards optimal disease control. Lancet Gastroenterol Hepatol (Sep 2025)
Jawed R. 2025. Prevalence and clinical significance of autoantibodies to sulphite oxidase and glycogen phosphorylase in Chinese primary biliary cholangitis patients. Mol Biol Rep (Jun 2025)
Mabuchi S, et al. 2025. Autoimmune Polyglandular Syndrome Type 3b: A Key to Diagnosing Autoimmune Gastritis and Asymptomatic Primary Biliary Cholangitis. Eur J Case Rep Intern Med (2025)
Lim J, Choi J. 2025. Reply to: "Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?". JHEP Rep (Jun 2025)
Zeng ZY, et al. 2025. Anti-RPL30 as a novel biomarker for enhanced diagnosis of autoantibody-negative primary biliary cholangitis. World J Gastroenterol (May 2025)
Vögelin M, Kremer AE. 2025. Advancing care in primary biliary cholangitis: emerging insights and novel therapies. Expert Opin Pharmacother (Jul 2025)
Zaidi MH, et al. 2025. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JGH Open (Jun 2025)
Giannini EG, et al. 2025. Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some? JHEP Rep (Jun 2025)
Wang KL, et al. 2025. [Research progress of intestinal-hepatic axis in primary biliary cholangitis]. Zhonghua Nei Ke Za Zhi (Jun 2025)
Li T, Jing W. 2025. Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization. Front Med (Lausanne) (2025)
Castiella A, et al. 2025. Identifying patients with undiagnosed primary biliary cholangitis using a clinical management process. Ann Hepatol (Jun 2025)
Xia Q, et al. 2025. The phenotypic and functional characteristics of intrahepatic CD69CD103 tissue-resident MAIT cells in primary biliary cholangitis. J Autoimmun (Jun 2025)
Zhu H, et al. 2025. Cholesterol-modified prognostic nutritional index as an independent prognostic biomarker in primary biliary cholangitis patients. BMC Gastroenterol (May 2025)
Kobayashi H, et al. 2025. Biochemical and Plasma Lipid Responses to Pemafibrate in Patients With Primary Biliary Cholangitis and Dyslipidemia: A Four-Year Analysis. Cureus (Apr 2025)
Klatzkow H, et al. 2025. Primary Biliary Cholangitis in 2025: A New Frontier. Am J Gastroenterol (May 2025)
Chen PT, Chen HW. 2025. Reply to "comment on risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in taiwan". J Formos Med Assoc (May 2025)
Gadour E, et al. 2025. Efficacy and Safety of Novel Oral Anti-Cholestatic Agents for Primary Biliary Cholangitis: Meta-Analyses and Systematic Review. Pharmaceuticals (Basel) (May 2025)
Niu J, et al. 2025. The causal effects of primary biliary cholangitis on irritable bowel syndrome: a mendelian randomization study. Int J Surg (Jul 2025)
Dahl MLN, et al. 2025. Anti-Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis. Hepatol Res (Aug 2025)
Zheng L, et al. 2025. [The characteristics and clinical values of peripheral T lymphocytic subsets and functional changes in primary biliary cholangitis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (May 2025)
URSO Calculator
Jul 27th, 2025 The PBC Ireland Patient Registry is now LIVE!
Jul 26th, 2025 PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC
May 8th, 2025 PBC Ireland Launched!
© PBC Ireland 2025 - 2025 | Terms | Privacy & GDPR
